Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
 
Become a Member | Sign in
Home>Resources>Webcasts>This Webcast
  Webcasts

Novel Histamine Receptor Family Antagonists by Fragment Screening and Molecular Modelling

Mark Slack, Group Leader Cellular Assays, Evotec, speaking at MedChem Europe
Date Posted: Sunday, June 12, 2011

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Related Content

Evotec Wins Research Grant to Advance H3 Receptor Antagonist Programme into the Clinic
A EUR 1.5 million BMBF grant will advance the H3 receptor antagonist programme through Phase I clinical studies.
Tuesday, April 27, 2010
Evotec and Boehringer Ingelheim Extend and Broaden Research Collaboration
Strategic research collaboration continues for another 4 years at a value of EUR 15 million plus milestones and royalties
Monday, November 09, 2009
Evotec Receives a EUR 2.5 Million Milestone Payment in its Research Collaboration with Boehringer Ingelheim
Evotec AG today announced that it has achieved another milestone in its research collaboration with Boehringer Ingelheim.
Thursday, October 22, 2009
Procter & Gamble Selects Evotec as Provider of Pharmaceutical Discovery and Chemical Development Services
P&GP will access a wide range of discovery and preclinical expertise offered by Evotec, ranging from assay development, screening, medicinal and computational chemistry to scale-up and pharmaceutical manufacture.
Monday, July 25, 2005
Evotec OAI and Novartis Pharma AG Sign Lead Discovery Collaboration

Thursday, April 10, 2003
Evotec OAI collaboration with KeyNeurotek and IMTM

Wednesday, January 15, 2003
Evotec OAI Names President of Discovery Services

Tuesday, December 10, 2002
Evotec OAI Enters into Agreement With Venture Capital Firm

Thursday, November 14, 2002
Scientific News
Keeping Tumor Growth at Bay
Engineers at Washington University in St. Louis found a way to keep a cancerous tumor from growing by using nanoparticles of the main ingredient in common antacid tablets.
Future of Medicine Could be Found in a Tiny Crystal Ball
A Drexel University materials scientist has discovered a way to grow a crystal ball in a lab. Not the kind that soothsayers use to predict the future, but a microscopic version that could be used to encapsulate medication in a way that would allow it to deliver its curative payload more effectively inside the body.
Improving Delivery of Poorly Soluble Drugs Using Nanoparticles
A technology that could forever change the delivery of drugs is undergoing evaluation by the Technology Evaluation Consortium™ (TEC). Developed by researchers at Northeastern University, the technology is capable of creating nanoparticle structures that could deliver drugs into the bloodstream orally – despite the fact that they are normally poorly soluble.
Faster Drug Discovery?
Startup develops more cost-effective test for assessing how cells respond to chemicals.
New Mechanism of Antitumor Action Identified
A team of UAB researchers and collaborators from the Catalan biotech company Ability Pharmaceuticals (UAB Research Park), have described a new mechanism of anti-tumour action, identified during the study and development of the new drug ABTL0812.
Nanoparticles Deliver Tumor Suppressors to Damaged Livers
UT Southwestern Medical Center chemists have successfully used synthetic nanoparticles to deliver tumor-suppressing therapies to diseased livers with cancer, an important hurdle scientists have been struggling to conquer.
Experimental Combination Surprises with Anti-HIV Effectiveness
A compound developed to protect the nervous system from HIV surprised researchers by augmenting the effectiveness of an investigational antiretroviral drug beyond anything expected.
A New Type of Anticancer Agent
Success in the development of a ?-tubulin specific inhibitor.
Nanoparticles Proven Effective Against Antibiotic-Resistant “Superbugs”
In the ever-escalating evolutionary battle with drug-resistant bacteria, humans may soon have a leg up thanks to adaptive, light-activated nanotherapy developed by researchers at the University of Colorado Boulder.
Versatile New Molecule-Building Technique
Chemists at The Scripps Research Institute (TSRI) have devised a new and widely applicable technique for building potential drug molecules and other organic compounds.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!